First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly speaks to ecancer about the 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial. The study compared liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The key findings were that first-line NALIRIFOX demonstrated clinically meaningful and statistically significant improvement in OS and PFS compared with nab-paclitaxel + gemcitabine in patients with mPDAC. The NALIRIFOX safety profile was consistent with the profiles of the regimen components and generally manageable.